Moreover, we demonstrated the existence of an overall decrease in the expression of all SST/CORT-system components [ligands (SST/CORT) and SSTRs] in GBM-samples, compared to control-samples, being this downregulation statistically significant for all components, except for SSTR5. This might be clinically relevant, as SSAs responsiveness is critically dependent on the presence of SSTRs, and because SSAs treatment (which preferential bind to SSTR2) has become the mainstay of medical therapy for tumour control in different neuroendocrine-pathologies [18, 50]. The gene discussed is SSTR2; the disease is neoplasm.